A growing number of Americans are trying popular weight-loss drugs touted by celebrities, health care providers and others.

How does Innovent Biologics' mazdutide, a groundbreaking dual GLP-1/glucagon receptor drug just approved in China, compared to Wegovy and Zepbound? Read more here.

CVS adds Wegovy to its top formularies and bolsters its Weight Management program, aiming to expand access while cutting costs.

Lifestyle therapy may not be enough to improve outcomes for patients with HF and obesity, but careful risk evaluation and ...

China’s nascent weight loss drug market is poised for rapid growth ... it appeared just as effective as Lilly’s bestselling Zepbound in helping patients lose weight. The treatment also reduced liver ...

Protagonist Therapeutics is taking aim directly at Eli Lilly's obesity treatment with a newly announced drug that uses the same mechanism.

Crumbl has built its viral desserts into a big business, with franchisees operating over 1,100 stores in the US, Puerto Rico ...

Eli Lilly stock currently trades below its 50-week average, offering a strong entry point despite continued dominance in ...

Suzhou-based Innovent Biologics secured approval last week for its treatment mazdutide. Read more at straitstimes.com. Read ...

What is Ozempic teeth? Here is what you need to know about how the weight loss drug Ozempic may be impacting your health.

China has approved a new weight-loss drug that is poised to rival Novo Nordisk and Eli Lilly's popular GLP-1 treatments, ...

This week, there are new and surprising opportunities. The week begins on Sunday, December 22, when the moon in Libra trines Pluto in your own sign of Aquarius and your house of physical energy. Today ...